R 115777
| Code | Size | Price |
|---|
| TAR-T26012-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
R 115777 is an inhibitor of farnesyl transferase.
CAS:
192185-68-5
Formula:
C27H22Cl2N4O
Molecular Weight:
489.4
Purity:
0.98
SMILES:
Cn1cncc1C(N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1
References
1. Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs. 2007 Mar;16(3):381-92. Review. PubMed PMID: 17302532.
2. Lavelle F. American Association for Cancer Research 1999: 10-14 April, Philadelphia, Pennsylvania. Expert Opin Investig Drugs. 1999 Jun;8(6):903-9. PubMed PMID: 15992139.
3. Lavelle F. American Association for Cancer Research 1998: promises and prospects for the next century. Expert Opin Investig Drugs. 1998 Jun;7(6):1015-21. PubMed PMID: 15992013.
4. Morgan MA, Ganser A, Reuter CW. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia. 2003 Aug;17(8):1482-98. Review. PubMed PMID: 12886235.